MET and neoplasm: We identified additional potential mechanisms of acquired Osimertinib resistance in the tumor rebiopsy, such as the MET p.H1112Y variant, MET receptor upregulation (MET-IHC 3+ in 70% and 2+ in 30% of tumor cells), and low-level MET amplification (61% of tumor cells with ≥4 MET copies by FISH analysis) as well as TP53 mutation (p.K320*).